Hammer GD - Search Results

1

Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin.

Heaton JH, Wood MA, Kim AC, Lima LO, Barlaskar FM, Almeida MQ, Fragoso MC, Kuick R, Lerario AM, Simon DP, Soares IC, Starnes E, Thomas DG, Latronico AC, Giordano TJ, Hammer GD. Heaton JH, et al. Among authors: hammer gd. Am J Pathol. 2012 Sep;181(3):1017-33. doi: 10.1016/j.ajpath.2012.05.026. Epub 2012 Jul 15. Am J Pathol. 2012. PMID: 22800756 Free PMC article.

2

Role of the inhibin/activin system and luteinizing hormone in adrenocortical tumorigenesis.

Beuschlein F, Looyenga BD, Reincke M, Hammer GD. Beuschlein F, et al. Among authors: hammer gd. Horm Metab Res. 2004 Jun;36(6):392-6. doi: 10.1055/s-2004-814584. Horm Metab Res. 2004. PMID: 15241730 Review.

3

Management of patients with adrenal cancer: recommendations of an international consensus conference.

Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M, Worden FP. Schteingart DE, et al. Among authors: hammer gd. Endocr Relat Cancer. 2005 Sep;12(3):667-80. doi: 10.1677/erc.1.01029. Endocr Relat Cancer. 2005. PMID: 16172199 Review.

4

Adrenocortical cells with stem/progenitor cell properties: recent advances.

Kim AC, Hammer GD. Kim AC, et al. Among authors: hammer gd. Mol Cell Endocrinol. 2007 Feb;265-266:10-6. doi: 10.1016/j.mce.2006.12.028. Epub 2007 Jan 19. Mol Cell Endocrinol. 2007. PMID: 17240045 Free PMC article. Review.

5

Genetic removal of Smad3 from inhibin-null mice attenuates tumor progression by uncoupling extracellular mitogenic signals from the cell cycle machinery.

Looyenga BD, Hammer GD. Looyenga BD, et al. Among authors: hammer gd. Mol Endocrinol. 2007 Oct;21(10):2440-57. doi: 10.1210/me.2006-0402. Epub 2007 Jul 24. Mol Endocrinol. 2007. PMID: 17652186

6

The molecular genetics of adrenocortical carcinoma.

Barlaskar FM, Hammer GD. Barlaskar FM, et al. Among authors: hammer gd. Rev Endocr Metab Disord. 2007 Dec;8(4):343-8. doi: 10.1007/s11154-007-9057-x. Rev Endocr Metab Disord. 2007. PMID: 17934868 Review. No abstract available.

7

Evaluation of telomere length maintenance mechanisms in adrenocortical carcinoma.

Else T, Giordano TJ, Hammer GD. Else T, et al. Among authors: hammer gd. J Clin Endocrinol Metab. 2008 Apr;93(4):1442-9. doi: 10.1210/jc.2007-1840. Epub 2008 Jan 15. J Clin Endocrinol Metab. 2008. PMID: 18198226

8

Targeted disruption of beta-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex.

Kim AC, Reuter AL, Zubair M, Else T, Serecky K, Bingham NC, Lavery GG, Parker KL, Hammer GD. Kim AC, et al. Among authors: hammer gd. Development. 2008 Aug;135(15):2593-602. doi: 10.1242/dev.021493. Epub 2008 Jul 3. Development. 2008. PMID: 18599507

9

Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.

Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, Thomas DG, Giordano TJ, Ben-Josef E, Hammer GD. Barlaskar FM, et al. Among authors: hammer gd. J Clin Endocrinol Metab. 2009 Jan;94(1):204-12. doi: 10.1210/jc.2008-1456. Epub 2008 Oct 14. J Clin Endocrinol Metab. 2009. PMID: 18854392 Free PMC article.

10

SUMOylation inhibits SF-1 activity by reducing CDK7-mediated serine 203 phosphorylation.

Yang WH, Heaton JH, Brevig H, Mukherjee S, Iñiguez-Lluhí JA, Hammer GD. Yang WH, et al. Among authors: hammer gd. Mol Cell Biol. 2009 Feb;29(3):613-25. doi: 10.1128/MCB.00295-08. Epub 2008 Nov 17. Mol Cell Biol. 2009. PMID: 19015234 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

137 results

Search Page

Filters